Leitat has been awarded second position in the Impact Expected category at the EARTO Innovation Awards 2026, which recognize innovations with the highest potential to generate economic and societal impact in Europe.
The award was given to OGYX, an Organ-on-a-Chip (OoC) platform developed by Leitat that combines high-throughput screening capabilities with advanced biological models to support drug discovery and personalized medicine.
The technology is based on a gravity-driven microfluidic plate designed to reproduce human biological functions in a more accurate and efficient way. Its membrane-free design enables 2D and 3D cell cultures without the need for pumps or tubing, making it easier to use and scalable for industrial applications. It also includes a Design for Detection (D4D) approach, enabling robust results compatible with standard laboratory equipment.
According to the jury, OGYX helps accelerate the adoption of Organ-on-a-Chip technologies by offering a robust, cost-effective solution aligned with new European regulations. Its potential will support the transition towards more predictive biomedical research models, significantly reduce the use of animals in testing, and foster the development of personalized treatments.
The EARTO Innovation Awards, organized by the European Association of Research and Technology Organisations (EARTO), have been recognizing outstanding innovations from European research and technology organizations since 2009. In the 2026 edition, Leitat was distinguished among the top European initiatives in the Impact Expected category, which rewards technologies not yet commercialized but with high impact potential.
Pooya Azizian has led the OGYX project and has been developed by Leitat’s Diagnostic Devices Department, with the contribution of a multidisciplinary team of researchers and professionals. The recognition received at the EARTO Innovation Awards by Gerard Musterni, Evelyn Moreno and Vincent Jamier highlights the team’s expertise and commitment to developing innovative solutions for biomedical research and personalised medicine.
We would like to sincerely thank EARTO and the evaluation committee for this recognition and for their continued efforts in promoting innovation across Europe.
